Capsule Endoscopy Market Outlook 2026–2033: Size, Share and 8.1% CAGR Explained
The global capsule endoscopy market was valued at USD 475.7 million in 2025. It is estimated at USD 511.7 million in 2026 and projected to reach USD 880.5 million by 2033, a CAGR of 8.1% from 2026 to 2033. North America led with a 43.5% revenue share in 2025, while Asia Pacific is expected to record the fastest growth. The main drivers are the rising prevalence of gastrointestinal (GI) diseases and colon cancer, demand for minimally invasive diagnostics, and newer, more advanced capsules.
What Capsule Endoscopy Does, and Why Hospitals Are Adopting It
Capsule endoscopy is a non-invasive technique in which the patient swallows a wireless capsule with a miniature camera. The capsule captures high-resolution images of the GI tract. It is used to investigate obscure GI bleeding, Crohn’s disease, small bowel tumors, colorectal and esophageal cancers, and celiac disease. Unlike conventional endoscopy, it can image the entire small intestine without sedation or insertion, which is why gastroenterology departments keep adding it to their services.
The figures in this article draw on Grand View Research’s market analysis. Continue your research with their Prism AI tool for more data and insights.
The Insight Most Competitors Miss: Timing Is the Real Value Driver
Most coverage of the capsule endoscopy market focuses on device launches. A 2025 case study cited in the source suggests that clinical workflow may matter just as much. The study examined 562 patients evaluated with small-bowel capsule endoscopy, and 131 of them had overt bleeding and were analyzed. Detection rates for the bleeding source stayed around 48–54% regardless of timing. What changed was the outcome for patients where no source was found. Their one-year rebleeding rate was about 2% when the procedure took place within 14 days of bleeding, compared with 20% when it was delayed beyond 14 days.
From a market view, this suggests demand may increasingly favor systems that shorten the path from bleeding event to result. That means faster setup, automatic data upload and AI-assisted triage. The source draws the same conclusion, noting that hospitals are likely to invest in faster-turnaround systems and that clinical evidence of this kind supports wider reimbursement acceptance. This is our reading of the data and not a measured market statistic.
Download a free sample report or claim your copy of this full market intelligence report
Segment Leadership in the Capsule Endoscopy Market
By type, small bowel capsule endoscopy led with a 54.7% revenue share in 2025. Colon capsule endoscopy is expected to grow at the fastest CAGR, supported by awareness of colon cancer and expanding screening programs. The CDC reported 147,931 new colorectal cancer cases in the U.S. in 2022 and 53,779 related deaths in 2023.
By application, obscure GI bleeding (OGIB) held the largest share at 45.3%, while small intestine tumor is the fastest-growing area. The American Cancer Society estimated about 13,920 new small intestine cancer cases in the U.S. in 2024.
By end use, hospitals held 55.5% of revenue in 2025 and are also expected to grow at the fastest CAGR. Outpatient facilities are projected to grow at a significant CAGR as daycare and ambulatory centers take on more colon screening, helped by faster recovery and minimal discomfort.
Taken together, the leading segments (small bowel, OGIB, hospitals) reflect where the technology is established today. The fastest-growing ones (colon, small intestine tumor) show where the capsule endoscopy market is expanding, from diagnosing bleeding toward screening and oncology.
Looking for more in-depth data focusing on specific segments or regions? Get this report customized with inclusion of custom data sets to suit your exact business needs
Regional Outlook: Where Capsule Endoscopy Demand Is Building
North America’s 43.5% share in 2025 is linked to a high burden of Crohn’s disease, GI bleeding, celiac disease, ulcerative colitis and colon cancer. The Crohn’s & Colitis Foundation estimated that over 100,000 American youth under age 20 live with IBD. The U.S. held the largest share within the region, helped by the growing preference for minimally invasive procedures and manufacturers seeking FDA approval first.
Europe is expected to grow at a significant CAGR. The source credits a relatively less stringent device approval process, high disposable income and established healthcare infrastructure. In Germany, about one in eight cancer cases affects the colon or rectum, and in 2022 roughly 29,956 men and 24,654 women were newly diagnosed.
Asia Pacific is projected to be the fastest-growing region, driven by large patient pools, strong healthcare innovation and growing investment by market players. In China, training hubs such as the Olympus China Medical Training & Education Center, with bases in Shanghai, Beijing and Guangzhou, support clinician readiness. Latin America and the Middle East & Africa are both expected to grow at considerable rates. Brazil and Argentina lead in Latin America, and in MEA the World Gastroenterology Organisation has backed endoscopy training centers in cities such as Lagos, Nairobi, Blantyre and Addis Ababa.
Innovation, Regulation and Competition
The industry is highly innovative, with medium merger and acquisition activity. In the U.S., the FDA regulates capsule endoscopy as a Class II device. Several recent milestones show the direction of travel:
- In January 2024, the FDA cleared NaviCam SB by AnX Robotica for adults and children aged two and above.
- In January 2024, the FDA also approved AnX Robotica’s AI-powered tool for analyzing small bowel capsule images.
- In May 2024, Medtronic received FDA clearance for its next-generation PillCam Genius SB kit.
- In December 2024, Asian Institute of Gastroenterology Hospital introduced PillBotT, a remote-controlled disposable capsule from Endiatx.
- In January 2025, CapsoVision received FDA clearance for pediatric use of CapsoCam Plus in patients aged two and older.
- In November 2025, CapsoVision applied for Breakthrough Device Designation for a variant aimed at early-stage pancreatic cancer screening.
The leading participants in the capsule endoscopy market include CapsoVision, Shangxian Minimal Invasive Inc., INTROMEDIC, Medtronic, Olympus, AnX Robotics, JINSHAN Science & Technology (Group) Co., Ltd., Check-Cap, RF Co., Ltd. and BioCam. Training also plays a role in adoption, with courses such as UEG’s “A Primer In Capsule Endoscopy” preparing clinicians as AI-assisted and magnetically controlled capsules spread.
Final Takeaway
The capsule endoscopy market is moving from a niche small-bowel tool to a broader platform spanning bleeding diagnosis, colon screening and oncology. With the market expected to reach USD 880.5 million by 2033, buyers and investors should watch AI-assisted analysis, pediatric clearances and faster clinical workflows.
Check Out Our Dedicated Business Offerings –
U.S. Healthcare Facility Mapping & Intelligence Platform: Get facility-level intelligence to guide smarter decisions. Sign up Today
- Art
- Causes
- Crafts
- Dance
- Drinks
- Film
- Fitness
- Food
- Jeux
- Gardening
- Health
- Domicile
- Literature
- Music
- Networking
- Autre
- Party
- Religion
- Shopping
- Sports
- Theater
- Wellness